Donepezil Hydrochloride Tablet, Film Coated
Product Images NDC 46708-296

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 46708-296). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

10 mg 30's Bottle Pack (Donepezil 10mg)

Donepezil Hydrochloride Tablets, USP 10 mg film-coated oral tablets packaging label. The label shows the NDC 46708-296-30, contains 30 tablets, and is manufactured by Alembic Pharmaceuticals Limited. Storage instructions specify 20 to 25°C, with dispensing and dosage instructions referencing accompanying information. The label includes the Alembic logo and barcode.*

FDA Label Image

5 mg 30's Bottle Pack (Donepezil 5mg)

Donepezil Hydrochloride Tablets, USP 5 mg film-coated tablets, packaged in a container of 30 tablets. Label shows NDC 46708-295-30 and is manufactured by Alembic Pharmaceuticals Limited. The label includes storage instructions and a barcode.*

FDA Label Image

Figure 1 (Donepezil Figure1)

A line graph showing the time-course of change from baseline in ADAS-cog scores over 24 weeks of treatment for Donepezil Hydrochloride 5 mg/day, 10 mg/day, and placebo. The vertical axis represents mean change in ADAS-cog score, with clinical improvement upward and clinical decline downward. The horizontal axis indicates weeks of drug treatment. Both Donepezil doses show improvement over placebo across the treatment period.*

FDA Label Image

Figure 10 (Donepezil Figure10)

A cumulative percentage line graph comparing patients treated with Donepezil hydrochloride 10 mg/day and placebo. The x-axis shows changes from baseline in ADCS-ADL-Severe scores, ranging from -20 to 20, and the y-axis shows the cumulative percentage of patients from 0 to 100%. Donepezil shows a steeper cumulative improvement compared to placebo over 6 months.*

FDA Label Image

Figure 2 (Donepezil Figure2)

This is a cumulative percentage graph showing the change from baseline in ADAS-cog scores for patients treated with Donepezil Hydrochloride 5 mg, 10 mg, and placebo over 24 weeks. The graph compares the percentage of patients who experienced specific score changes in cognitive function for each treatment group.*

FDA Label Image

Figure 3 (Donepezil Figure3)

A bar chart showing the frequency distribution of CIBIC plus scores at Week 24 for Donepezil Hydrochloride 10 mg/day, Donepezil Hydrochloride 5 mg/day, and placebo groups. The x-axis represents categories from markedly improved to markedly worse, and the y-axis shows the percentage of patients in each category for the three treatment groups.*

FDA Label Image

Figure 4 (Donepezil Figure4)

A line graph showing the time-course of change from baseline in ADAS-cog scores for patients over a 15-week drug treatment period. The graph compares Donepezil Hydrochloride at 10 mg/day and 5 mg/day dosages with placebo, indicating clinical improvement or decline in cognitive function over time, including mean values and error bars.*

FDA Label Image

Figure 5 (Donepezil Figure5)

A line graph showing the cumulative percentage of patients with specified changes from baseline ADAS-cog scores. Three treatment groups are plotted: placebo, donepezil hydrochloride 5 mg, and donepezil hydrochloride 10 mg, representing cognitive score changes over a range from -15 to 10 points.*

FDA Label Image

Figure 6 (Donepezil Figure6)

A bar chart showing the frequency distribution of CIBIC-plus scores at week 12 for patients treated with Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo. The horizontal axis displays categories from 'Markedly Improved' to 'Markedly Worse,' and the vertical axis shows the percentage of patients. Black bars represent 10 mg/day, gray bars 5 mg/day, and white bars placebo groups.*

FDA Label Image

Figure 7 (Donepezil Figure7)

A line graph illustrating the time course of change from baseline in SIB score over 6 months of drug treatment for Donepezil Hydrochloride 10 mg/day versus placebo. The graph shows clinical improvement in the Donepezil group compared to clinical decline or baseline stability in the placebo group, with data points at 0, 3, and 6 months and error bars reflecting standard error.*

FDA Label Image

Figure 8 (Donepezil Figure8)

A cumulative percentage curve graph comparing Donepezil Hydrochloride 10 mg/day to placebo in patients over six months. The x-axis shows SIB (Severe Impairment Battery) change from baseline, with values decreasing leftward. The y-axis shows the cumulative percentage of patients completing treatment. Donepezil shows a higher cumulative percentage at given SIB change points compared to placebo.*

FDA Label Image

Structure (Donepezil Structure)

Chemical structure of Donepezil Hydrochloride, showing its molecular framework including two methoxy groups attached to a fused ring system connected to a piperidine ring and a benzyl group, along with the hydrochloride salt.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.